相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of Macrophages in Cancer Development and Therapy
Ewa Cendrowicz et al.
CANCERS (2021)
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy
Robert Uger et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
Robyn J. Puro et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Targeting the 4-1BB costimulatory molecule through single chain antibodies promotes the human T-cell response
Salman Bagheri et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2020)
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
Marta Trub et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia
Isabel Weinhauser et al.
CANCERS (2020)
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Juliane Medler et al.
CELL DEATH & DISEASE (2019)
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
Yuan He et al.
NATURE COMMUNICATIONS (2019)
Interaction of tumor-associated macrophages and cancer chemotherapy
Irina Larionova et al.
ONCOIMMUNOLOGY (2019)
The macrophage checkpoint CD47: SIRPα for recognition of 'self' cells: from clinical trials of blocking antibodies to mechanobiological fundamentals
Jason C. Andrechak et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2019)
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRP&x251; axis
Hongcheng Yang et al.
CANCER MEDICINE (2019)
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL
Renee Bouwstra et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
Donastas Sakellariou-Thompson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
Shu Lian et al.
SCIENTIFIC REPORTS (2019)
Blocking don't eat me signal of CD47-SIRPα in hematological malignancies, an in-depth review
Atlantis Russ et al.
BLOOD REVIEWS (2018)
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
Rene J. Tavera et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Vanessa Buatois et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
Michael Poch et al.
ONCOIMMUNOLOGY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Marta Compte et al.
NATURE COMMUNICATIONS (2018)
Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
Elie Dheilly et al.
ANTIBODIES (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova et al.
CLINICAL CANCER RESEARCH (2017)
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Nan Guo Ring et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis
Eunee Koh et al.
BIOMATERIALS (2017)
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal et al.
CELL (2016)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye et al.
CLINICAL CANCER RESEARCH (2014)
Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
Jessica Ann Chacon et al.
PLOS ONE (2013)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
Agnes Wyzgol et al.
JOURNAL OF IMMUNOLOGY (2009)
Non-Hodgkin lymphoma: Diagnosis and treatment
SM Ansell et al.
MAYO CLINIC PROCEEDINGS (2005)
Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system
H Okazawa et al.
JOURNAL OF IMMUNOLOGY (2005)
分享论文
